Skip to main content

Meagan C. Fitzpatrick, PhD

Academic Title:

Assistant Professor

Primary Appointment:

Medicine

Phone (Primary):

(410) 706-8255

Education and Training

  • University of Notre Dame, B.S. in Biological Sciences, 2006
  • Yale University, Ph.D. in Epidemiology of Microbial Diseases, 2014
  • Postdoctoral Associate, Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, 2015-2016
  • Postdoctoral Fellow, Center for Vaccine Development, University of Maryland School of Medicine, 2016-2017

Biosketch

Dr. Fitzpatrick joined the faculty of the Center for Vaccine Development and Global Health (CVD) in 2017. She is also an affiliate of the Center for Infectious Disease Modeling and Analysis (CIDMA) at the Yale School of Public Health.

Dr. Fitzpatrick is an infectious disease transmission modeler. She applies these models to assess infectious disease control strategies, with particular focus on evaluating the cost-effectiveness of vaccines. Her research combines methods from economics and decision sciences with these epidemiological models, to provide policy recommendations and support evidence-based decision-making.

Current research priorities include evaluation of vaccines against rotavirus, pertussis, and RSV, as well as the response to the SARS-CoV2 pandemic and strategies to reduce maternal and infant mortality in low-income settings. Additional pathogens of interest have included rabies, influenza, HIV, Zika, and Ebola.

Research/Clinical Keywords

Infectious disease modeling; Transmission modeling; Dynamic modeling; Vaccine impact; Cost-effectiveness analysis; Medical decision-making; Pharmacoeconomics; Global health; One Health; Maternal vaccination; Neonatal vaccination; Rabies; Pertussis; Rotavirus; Influenza; Zika; Ebola; COVID-19; SARS-CoV2

Highlighted Publications

Moghadas, SM; Shoukat, A; Fitzpatrick, MC; Wells, CR; Sah, P; Pandey, A; Sachs, JD; Wang, Z; Meyers, LA; Singer, BH; Galvani, AP. (2020) Projecting hospital utilization during the COVID-19 outbreaks in the United States. Proceedings of the National Academy of Sciences, USA. Online first; 10.1073/pnas.2004064117.

Galvani, AP; Parpia, AS; Foster, EM; Singer, BH; Fitzpatrick, MC. (2020) Improving the prognosis of healthcare in the United States. The Lancet. 395(10223): 15 – 21.

Fitzpatrick, MC; Bauch, CT; Townsend, JP; Galvani, AP. (2019) Modelling microbial infection to address global health challenges. Nature Microbiology. 4(10): 1612 – 1619.

Sah, P; Alfaro-Murillo, JA; Fitzpatrick, MC, Neuzil, KM; Meyers, LA; Singer, BH; Galvani, AP. (2019) Future epidemiological and economic impacts of universal influenza vaccines. Proceedings of the National Academy of Sciences, USA. 116(41): 20786 – 20792.

Fitzpatrick, MC; Singer, BH; Hotez, PJ; Galvani, AP. (2017) Saving lives efficiently across sectors: The need for a Congressional cost-effectiveness committee. The Lancet. 6736(17): 17 – 19.

Additional Publication Citations

32. Wells, CR*; Fitzpatrick, MC*; Sah, P; Shoukat, A; Pandey, A; El-Sayed, AM; Singer, BH; Moghadas, SM; Galvani, AP. Projecting the demand for ventilators at the peak of COVID-19 outbreaks in the United States. The Lancet, in press. *Authors contributed equally to this paper.

31. Moghadas, SM; Shoukat, A; Fitzpatrick, MC; Wells, CR; Sah, P; Pandey, A; Sachs, JD; Wang, Z; Meyers, LA; Singer, BH; Galvani, AP. (2020) Proceedings of the National Academy of Sciences, USA. Projecting hospital utilization during the COVID-19 outbreaks in the United States. Online first; 10.1073/pnas.2004064117.

30. Galvani, AP; Parpia, AS; Foster, EM; Singer, BH; Fitzpatrick, MC. (2020) Improving the prognosis of healthcare in the United States. The Lancet. 395(10223): 15 – 21.

29. Alfaro-Murillo, JA; Ávila-Agüero, ML; Fitzpatrick, MC; Crystal, CJ; Falleiros-Arlant, LH; Galvani, AP. (2020) The case for replacing the live oral polio vaccine with the inactivated vaccine throughout the Americas. The Lancet. 395(10230): 1163 – 1166.

28. Craig, R; Kunkel, E; Crowcroft, N; Fitzpatrick, MC; de Melker, H; Althouse, BM; Merkel, T; Scarpino, SV; Koelle, K; Friedman, L; Arnold, C; Bolotin, S. (2020) Asymptomatic infection and transmission of pertussis in households: a systematic review. Clinical Infectious Diseases. 70(1): 152 – 161.

27. Fitzpatrick, MC; Bauch, CT; Townsend, JP; Galvani, AP. (2019) Modelling microbial infection to address global health challenges. Nature Microbiology. 4(10): 1612 – 1619. 

26. Sah, P; Alfaro-Murillo, JA; Fitzpatrick, MC, Neuzil, KM; Meyers, LA; Singer, BH; Galvani, AP. (2019) Future epidemiological and economic impacts of universal influenza vaccines. Proceedings of the National Academy of Sciences, USA. 116(41): 20786 – 20792.

25. Wells, CR; Pandey, A; Parpia, AS; Fitzpatrick, MC; Meyers, LA; Singer, BH; Galvani, AP. (2019) Ebola vaccination in the Democratic Republic of the Congo. Proceedings of the National Academy of Sciences, USA. 116(20): 10178 – 10183.

24. Beyene, TJ; Fitzpatrick, MC; Galvani, AP; Mourits, MCM; Revie CW; Cernicchiaro N; Sanderson MW; Hogeveen H. (2019) Impact of One-Health framework on vaccination cost-effectiveness: A case study of rabies in Ethiopia. One Health. 8:100103.

23. España, G; Yao, Y; Anderson, KB; Fitzpatrick, MC; Smith, DL; Morrison, AC; Wilder-Smith, A; Scott, TW; Perkins, TA. (2019) Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure. PLoS Neglected Tropical Diseases. 13(7): e0007482.

22. Neuzil, KM; Fitzpatrick, MC. (2019) The Impact of Influenza Vaccine: It’s the Size of the Glass. Clinical Infectious Diseases, ciz078. https://doi.org/10.1093/cid/ciz078.

21. Pandey, A; Fitzpatrick, MC; Galvani AP. (2019) Metrics and benchmarks for HIV transition – Authors’ reply. The Lancet HIV. 6(3): e150.

20. Galvani, AP; Pandey, A; Fitzpatrick, MC; Medlock, J; Gray, GE. (2018) Defining control of HIV epidemics. The Lancet HIV. 5(11): 667 – 670.

19. Fitzpatrick, MC; Gray, GE; Galvani, AP. (2018) Facing the Future – the Challenge of Vanquishing HIV for the Next Generation. JAMA Pediatrics. 172(7): 609 – 610. 

18. Sah, P; Medlock, J; Fitzpatrick, MC; Singer, BH; Galvani, AP. (2018) Optimizing the impact of low-efficacy influenza vaccines. Proceedings of the National Academy of Sciences, USA. 115(20): 5151 – 5156.          

17. Durham, DP; Fitzpatrick, MC; Ndeffo-Mbah, ML; Parpia, MS; Michael, NL; Galvani, AP. (2018) Evaluating Zika vaccination strategies in the Americas. Annals of Internal Medicine. 168(9): 621 – 630.

16. Haidara, FC; Tapia, MD; Sow SO; Doumbia, M; Coulibaly, F; Diallo, F; Traoré, A; Kodio, M; Kelly, CL; Fitzpatrick, MC; Kotloff, K; Victor, JC; Neuzil, K. (2018) Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants. Journal of Infectious Diseases. 218(4): 606 – 613.

15. Fitzpatrick, MC; Singer, BH; Hotez, PJ; Galvani, AP. (2017) Saving lives efficiently across sectors: the need for a Congressional cost-effectiveness committee. The Lancet. 6736(17): 17 – 19.

14. Galvani, AP; Fitzpatrick, MC; Vermund, SH; Singer, BH. (2017) Fund global health: Save lives and money. Science. 356: 1018 – 1019.

13. Sah, P; Fitzpatrick, MC; Pandey, A; Galvani, AP. (2017) HIV criminalization exacerbates subpar diagnosis and treatment across the United States: response to the ‘Association of HIV diagnosis rates and laws criminalizing HIV exposure in the United States.’ AIDS. 31(17): 2437 – 2439.

12. Galvani, AP; Durham DP; Vermund, SH; Fitzpatrick MC. (2017) California Universal Health Care: an economic stimulus and life-saving proposal. The Lancet. 390(10106): 2012 – 2014.

11. Fitzpatrick, MC; Shah, HA; Pandey, A; Bilinski, AM; Kakkar, M; Clark, AD; Townsend, JP; Abbas, SS; Galvani, AP. (2016) One Health approach to cost-effective rabies control in India. Proceedings of the National Academy of Sciences, USA. 113(51): 14574 – 14581. 

10. Bilinski, AM; Fitzpatrick, MC; Rupprecht, CE; Paltiel, AD; Galvani, AP. (2016) Optimal frequency of rabies vaccination campaigns in sub-Saharan Africa. Proceedings of the Royal Society B. 283(1842): 20161211.

9. Fitzpatrick, MC; Wenzel, NS; Scarpino, SV; Althouse, BM; Atkins, KE; Galvani, AP; Townsend, JP. (2016) Cost-effectiveness of next-generation vaccines: the case of pertussis. Vaccine. 34(29): 3405 – 3411. 

8. Atkins, KE*; Fitzpatrick, MC*; Galvani, AP; Townsend, JP. (2016) Cost-effectiveness of pertussis vaccination during pregnancy in the US. American Journal of Epidemiology. 183(12): 1159 – 1170. *Authors contributed equally to this paper.

7. DeAngelis, H; Scarpino, SV; Fitzpatrick, MC; Galvani, AP; Althouse, BM. (2016) Epidemiological and economic impacts of priming with whole-cell Bordetella pertussis vaccine. JAMA Pediatrics. 170(5): 459 – 465.

6. Alfaro-Murillo, JA*; Parpia, AS*; Fitzpatrick, MC*; Tamagnan, JA; Medlock, J; Ndeffo-Mbah, ML; Fish, D; Ávila-Agüero, ML; Marín, R; Ko, AI; Galvani, AP. (2016) A cost-effectiveness tool for informing policies on Zika virus control. PLoS Neglected Tropical Diseases. 10(5): e000473. *Authors contributed equally to this paper.

5. Fitzpatrick, MC; Hampson, K; Cleaveland, S; Mzimbiri, I; Lankester, F; Lembo, T; Meyers, LA; Paltiel, AD; Galvani, AP. (2014) Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania. Annals of Internal Medicine. 160(2): 91 – 100

4. Dunn, JM; Krause, PJ; Davis, S; Vannier, EG; Fitzpatrick, MC; Rollend, L; Belperron, AA; States, SL; Stacey A; Bockenstedt, LK; Fish, D; Diuk-Wasser, MA. (2014) Borrelia burgdorferi promotes the establishment of Babesia microti in the northeastern United States. PLoS ONE. 9(12): e115494

3. Fitzpatrick, MC; Hampson, K; Cleaveland, S; Meyers, LA; Townsend, JP; Galvani, AP. (2012) Potential for rabies control through dog vaccination in wildlife-abundant communities of Tanzania. PLoS Neglected Tropical Diseases. 6(8): e1796

2. Coulibaly, MB; Lobo, NF; Fitzpatrick, MC; Kern, M; Grushko, O; Thaner, DV; Traore, SF; Collins, FH; Besansky, NJ. (2007) Segmental duplication implicated in the genesis of inversion 2Rj of Anopheles gambiae. PLoS ONE. 2(9): e849

1. Stump, AD; Fitzpatrick, MC; Lobo, NF; Traore, S; Sagnon, NF; Costantini, C; Collins, FH; Besansky, NJ. (2005) Centromere-proximal differentiation and speciation in Anopheles gambiae. Proceedings of the National Academy of Sciences, USA. 102(44): 15930 – 15935

 

Awards and Affiliations

Affiliate, Center for Infectious Disease Modeling and Analysis, Yale School of Public Health

Links of Interest

Google Scholar: https://scholar.google.com/citations?user=cCgEwiIAAAAJ&hl=en